IGRP Inhibitors
IGRP inhibitors belong to a distinct chemical class characterized by their ability to interact with and modulate the activity of the Islet-specific Glucose-6-Phosphatase Catalytic Subunit-related Protein (IGRP). This class of compounds typically consists of molecules that are designed to target specific binding sites or functional domains within the IGRP molecule. IGRP, a protein predominantly expressed in pancreatic islet cells, plays a pivotal role in glucose homeostasis and regulation. IGRP inhibitors function by perturbing the molecular interactions that dictate IGRP's enzymatic activity, which is involved in glucose metabolism pathways.
The chemical structures of IGRP inhibitors can vary widely, encompassing diverse arrangements of functional groups and molecular backbones that contribute to their binding affinity and specificity for IGRP. Researchers and scientists keenly investigate these inhibitors to uncover their mechanisms of action and implications in modulating glucose-related processes. The development and exploration of IGRP inhibitors represent a significant area of study within the broader field of molecular biology and biochemistry, as their effects on IGRP could have profound implications for understanding metabolic pathways and avenues for future scientific inquiries.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NVP-AUY922 | 747412-49-3 | sc-364551 sc-364551A sc-364551B sc-364551C sc-364551D sc-364551E | 5 mg 25 mg 100 mg 250 mg 1 g 5 g | $150.00 $263.00 $726.00 $1400.00 $2900.00 $11000.00 | 3 | |
NVP-AUY922 is a heat shock protein 90 (HSP90) inhibitor that disrupts the chaperone function of HSP90, leading to degradation of IGF-1R, a downstream target of IGRP. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a phosphoinositide 3-kinase (PI3K) inhibitor that blocks the PI3K pathway, including AKT, a key regulator of IGRP signaling, resulting in the suppression of IGRP-related signaling pathways. | ||||||
BMS-536924 | 468740-43-4 | sc-507397 | 5 mg | $285.00 | ||
BMS-536924 is a small molecule inhibitor of insulin-like growth factor receptor (IGF-1R), directly targeting IGRP signaling by preventing ligand binding and downstream signaling events. | ||||||
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $143.00 $260.00 | 1 | |
Also called OSI-906, this compound is an IGF-1R inhibitor that competes with IGF-1 for binding to the receptor, inhibiting downstream signaling pathways and impeding IGRP activation. | ||||||
PQ401 | 196868-63-0 | sc-221738 | 10 mg | $146.00 | ||
PQ401 inhibits IGRP signaling by targeting the IGF-1R pathway, disrupting the autophosphorylation of IGF-1R and subsequent activation of downstream signaling cascades. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
BMS-754807 is an ATP-competitive inhibitor of IGF-1R that interferes with receptor autophosphorylation, leading to decreased IGRP activation and downstream signaling. | ||||||
NVP-ADW742 | 475488-23-4 | sc-391129 sc-391129A | 5 mg 10 mg | $255.00 $480.00 | ||
NVP-ADW742 is an IGF-1R inhibitor that hinders receptor autophosphorylation and downstream signal transduction, thereby interfering with IGRP-mediated signaling pathways. | ||||||